GlaxoSmithKline Gross Profit Margin: 71.51%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GSK Gross Profit Margin Rankings
| Overall | 78th percentile | 897 of 4097 |
| Sector | 70th percentile | 112 of 381 in Healthcare |
| Industry | 72nd percentile | 5 of 18 in Drug Manufacturers - Major |
GSK Gross Profit Margin Range, Past 5 Years
| Minimum | 74.55% | Dec 2004 |
| Maximum | 80.51% | Mar 2006 |
| Average |
About Gross Profit Margin
Gross profit margin is the difference between sales and the cost of goods sold divided by revenue. It expresses the relationship between gross profit (sales - cost of goods sold) and sales revenue. More specifically, gross profit margin represents the percentage of each dollar of a company's revenue that is available to cover fixed costs after paying for the goods or services that were sold.
If a company produces widgets and earns $32 million in sales but pays $24 million for the items sold, then the company's gross profit margin would be ($32m - $24m)/$32m = %25.
Learn More
You may also be interested in these GSK related companies
GSK News
Interesting to see $GSK boasting about how it is repatriates its cash from European operations so fast these days. Probably a wise move.
about 5 days ago by bradloncar
about 5 days ago by bradloncar
GlaxoSmithKline plc's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 07, 3:30PM Seeking Alpha
Feb 07, 3:30PM Seeking Alpha
Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen
Feb 07, 11:33AM PR Newswire
Feb 07, 11:33AM PR Newswire
$GSK IR on Twitter. Smart example. "GSK to announce 2011 year-end results [today] at noon GMT. We'll be using the hashtag #GSKFY11"
about 6 days ago by BHSMITH
about 6 days ago by BHSMITH
Anacor Pharmaceuticals Down 14.4% After GlaxoSmithKline Pauses Ongoing Trials
Feb 06, 9:20AM Benzinga
Feb 06, 9:20AM Benzinga
Glaxo (GSK) Halts Enrollment in GSK '052 Phase 2b Following Recent Discovery (ANAC)
Feb 06, 8:31AM Street Insider
Feb 06, 8:31AM Street Insider
$ANAC reports partner GlaxoSmithKline $GSK has voluntarily paused enrollment of ongoing GSK '052 Phase 1, 2 Clinical Trials; ANAC halted
about 7 days ago by Street_Insider
about 7 days ago by Street_Insider
Drastic day for healthcare, esp. with pneumonia-deaths in clinical trials! http://stks.co/1qHP $THRX $BMY $GSK $INHX $IDIX
about 34 days ago by juliat333
about 34 days ago by juliat333
$GSK http://stks.co/1oDf $GSK looking intersting here, looking @ Feb 46 call or ITM 45's
about 37 days ago by _TheBlackSwan_
about 37 days ago by _TheBlackSwan_
RT @BloombergNews Drug approvals hit a seven-year high | http://stks.co/1n8c $GSK $JNJ
about 38 days ago by brittpierpoint
about 38 days ago by brittpierpoint
@Dostoevsky $HGSI has a few other drugs in development, in addition to a long-term relationship with $GSK
about 53 days ago by samlee22
about 53 days ago by samlee22
$GSK to sell 17 OTC brands in North America to $PBH for $660M; PBH shares up 7.8% pre-open
about 55 days ago by Street_Insider
about 55 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| OMC | 47.56 | -0.35 | -0.73% | 13.29B |
| BMY | 31.90 | -0.09 | -0.28% | 54.06B |
| EDAP | 2.11 | -0.04 | -1.86% | 27.68M |
| AMT | 63.29 | -0.50 | -0.78% | 25.05B |
| APA | 105.13 | -1.55 | -1.45% | 40.36B |
| ANR | 21.04 | -1.36 | -6.07% | 4.76B |
| AA | 10.29 | -0.35 | -3.29% | 10.95B |
| IO | 8.05 | -0.46 | -5.41% | 1.25B |
| VECO | 28.36 | 0.08 | 0.28% | 1.10B |
